TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04399772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy+ pathway
Description: The CFT+ intervention comprises 4 main components: (1) making sense of pain: context-based patient education focusing on the multidimensional nature of pain and disability, while reducing the threat of structural damage and correcting unhelpful beliefs; (2) exposure with control: graded exposure to painful, feared, or avoided activities with body relaxation; (3) lifestyle changes: encouraged to perform physical activity based on preference and taught strategies to manage stress and poor sleep, (4) focus on coping strategies in life and how these strategies influence the current situation.~After CFT+, patients can be offered the comparator pathway should that be clinically indicated from these criteria: the patient does not feel ready to stop treatment AND Analgesic treatment is inappropriate OR Social situation is problematic OR Significantly psychological distress that requires further treatment by psychologist. This decision is based on a multidisciplinary team conference.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interdisciplinary pain management pathway
Description: Treatment at the Interdisciplinary University Pain Center are based on elements from cognitive-behavioral therapy, Acceptance and Commitment Therapy, and Mindfulness-Based Stress Reduction programs.~Individualized combination of (1) medical treatment with a specialist pain consultant+specialist pain nurse (ie, individual adjustment of analgesics to improve effect and reduce side effects), (2) one or more of the following: individual consultations with a specialist pain psychologist, physiotherapist or social worker with cognitive-behavioral therapy training as well as participation in a group program with relaxation therapy, acceptance and commitment therapy or standardized mindfulness-based stress reduction programs.
Study: NCT03477214

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomechanical and electromyography mapping
Description: The vaginal tactile imaging probe will acquire biomechanical and electromyography high definition measurements for anterior and posterior compartments along entire vagina.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomechanical and electromyography mapping
Description: The vaginal tactile imaging probe will acquire biomechanical and electromyography high definition measurements for anterior and posterior compartments along entire vagina.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomechanical and electromyography mapping
Description: The vaginal tactile imaging probe will acquire biomechanical and electromyography high definition measurements for anterior and posterior compartments along entire vagina.
Study: NCT02819999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab Tesirine
Description: Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab Tesirine
Description: Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab Tesirine
Description: Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab Tesirine
Description: Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
Study: NCT02857933

Intervention type: OTHER
Group type: OTHER
Intervention: Physical Therapy
Description: One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.

Intervention type: OTHER
Group type: OTHER
Intervention: Physical Therapy
Description: One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
Study: NCT03594292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FASTFORWARDTM Bunion
Description: The participants will be assign to implantation of FASTFORWARDTM Bunion correction system surgery as a experimental group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional surgery
Description: The participants will assign to conventional surgery as a control group, the procedure is a standard treatment for the 1st metatarsal hallux valgus.
Study: NCT00969150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Drug: Levomilnacipran ER (flexible dose) Study drug is to be given orally, in capsule form, once daily, for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
Study: NCT01369394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: Computer-based tailoring system
Description: Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will generate educational messages based on participants' responses to survey questions. The intervention group will receive tailored educational messages, whereas the control group will receive generic educational messages. The tailored and generic educational messages will be presented as to look like web pages. However, the messages will only exist on the study computer, and will not be linked to any live server or website.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Computer-based tailoring system
Description: Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will generate educational messages based on participants' responses to survey questions. The intervention group will receive tailored educational messages, whereas the control group will receive generic educational messages. The tailored and generic educational messages will be presented as to look like web pages. However, the messages will only exist on the study computer, and will not be linked to any live server or website.
Study: NCT05135507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An integrated parenting intervention for families of children with developmental disabilities
Description: Deliver three training modules to parent and track program usage, psychological flexibility, parents' stress, parents mindfulness, and child behavior
Study: NCT04192968

Intervention type: OTHER
Intervention: Additional exams
Description: * Cortical auditory evoked potentials Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.~* Recording of cortical auditory evoked potentials in response to a click~* Realization of electrical potentials via the implant Followed up once a year during a visit scheduled for usual care, for 3 years, that to say up to 6 years post-implant.
Study: NCT01167010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol/Budesonide
Description: formoterol and budesonide will be administered at the 12/400 µg dosage, twice a da for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foraseq
Description: foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alenia
Description: Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
Study: NCT01847105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RevitaLens
Description: Multi-purpose disinfecting solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OptiFree PureMoist
Description: Multi-purpose disinfecting solution
Study: NCT00793572

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Syngeneic Bone Marrow Transplantation
Description: Undergo transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo radiotherapy
Study: NCT00123097

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chlorinated polyethylene elastomer
Description: Chlorinated polyethylene

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chlorinated polyethylene elastomer
Description: Chlorinated polyethylene
Study: NCT02159222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional physical therapy
Study: NCT03082573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: H.P. Acthar gel
Description: H.P. Acthar gel in treatment of Refractory RA
Study: NCT02819999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT00902993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: Solution, oral single and multiple dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03250078

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI/MRCP
Description: An MRI/MRCP plus IV gadolinium contrast with high resolution imaging of the pancreas will be performed annually
Study: NCT03887520

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood draw for Lp(a)
Description: Collect sample for Lipoprotein(a) testing
Study: NCT02361424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT00864
Description: PXT00864 is a fixed-dose combination of baclofen and acamprosate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT00864
Description: PXT00864 is a fixed-dose combination of baclofen and acamprosate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT00864
Description: PXT00864 is a fixed-dose combination of baclofen and acamprosate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04592172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedtime Routine Education
Description: The intervention aims to promote healthy sleep and improved developmental outcomes in infants. Individualized bedtime routine education, including such activities as a bath, teeth-brushing, reading stories, singing songs, and cuddling will be implemented by research assistants at the 12-month well-child visit. Reinforcement of the bedtime routine education will be implemented at the 15-month visit. Each individualized bedtime routine will incorporate 3-5 steps and a bedtime routine chart depicting those steps will be created and provided to the families. Families will receive materials for their bedtime routines, including a CuddleBright kit, 1-2 additional bedtime books, toothbrush/toothpaste , and the created bedtime chart. On top of that, families will also receive a children's book provided by Reach Out and Read through the study period.
Study: NCT00575432

Intervention type: RADIATION
Intervention: diffusion MRI
Description: diffusion MRI

Intervention type: RADIATION
Intervention: BOLD MRI
Description: BOLD MRI

Intervention type: OTHER
Intervention: Clinical Outcome
Description: Clinical outcome
Study: NCT03102021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erythropoietin
Description: 500 units/kg daily for 3 days at onset of acute kidney injury

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline 10 ml for 3 days
Study: NCT00432107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APO866
Description: APO866 is administered as 0.126 mg/m²/hr IV every 4 weeks for 4 consecutive days (96 hours) for a total of 3 cycles
Study: NCT03814291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI302
Description: 0.05mg/eye;Intraocular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI302
Description: 0.15mg/eye;Intraocular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI302
Description: 0.5mg/eye;Intraocular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI302
Description: 1mg/eye;Intraocular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI302
Description: 2mg/eye;Intraocular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI302
Description: 4mg/eye;Intraocular injection
Study: NCT02187601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPBA System
Description: MPBA is the new generation Multi Purpose Breath Analyzer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPBA System
Description: MPBA is the new generation Multi Purpose Breath Analyzer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreathID
Description: BreathID is the name of the original Exalenz breath analyzer system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreathID
Description: BreathID is the name of the original Exalenz breath analyzer system
Study: NCT02335723

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alteco LPS Adsorber
Description: Alteco® LPS Adsorber is a Class IIa medical device developed in accordance with existing international standards. Alteco® LPS Adsorber does not contain any pharmaceutical or toxic components.~Alteco® LPS Adsorber is used for the adsorption of LPS as endotoxins. The capturing component is a specially designed synthetic peptide developed for adsorption of endotoxin. The capturing component has high affinity to Lipid A, i.e. a constant component in the endotoxin molecule, which ensures efficient reduction of endotoxins from different bacterial species.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Exactly the same as Alteco LPS Adsorber but no peptide component has been attached to the matrix (i.e. there is no adsorber functionality)
Study: NCT00391274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment
Study: NCT00775112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pillow
Description: use of pillow for lumbar punctures
Study: NCT00623662

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative glucose infusion
Description: Glucose infusion from 15:00 on the day before the operation until beginning of surgery.
Study: NCT02066974

Intervention type: GENETIC
Intervention: hepatoma requiring radiotherapy
Description: hepatoma requiring radiotherapy
Study: NCT03138395

Intervention type: DIAGNOSTIC_TEST
Intervention: droplet digital PCR
Description: This study will use our droplet digital PCR (ddPCR) method to quantify and track peripheral blood plasma MAF in MDS and AML patients before, during and after chemotherapy treatment. Quantification of MAF from fingersticks and saliva samples will also be performed to determine feasibility of obtaining adequate circulating tumor DNA (ctDNA) for ddPCR. Results from this project will generate a non-invasive means to monitor cancer response and progression months before current clinical methods, and provide an opportunity to intervene before the patient relapses.
Study: NCT02543008

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical activity plus thoracic mobilization
Description: Information already included in arm/group descriptions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Information already included in arm/group descriptions.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Information already included in arm/group descriptions.
Study: NCT04307693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir / Ritonavir tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine sulfate
Description: Hydroxychloroquine sulfate tablet
Study: NCT02548494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Description: The control group will receive all traditional methods of treatment for DKA, including a placebo subcutaneous injection. The study group will receive the same treatment, but will be supplemented with a subcutaneous glargine injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV insulin
Description: The intravenous infusion of insulin at a weight-based fixed rate until ketosis has subsided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV insulin
Description: The intravenous infusion of insulin at a weight-based fixed rate until ketosis has subsided.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electrolyte Correction
Description: If the potassium level is greater than 6 mEq/L, do not administer potassium supplement. If the potassium level is 4.5-6 mEq/L, administer 10 mEq/h of potassium chloride. If the potassium level is 3-4.5 mEq/L, administer 20 mEq/h of potassium chloride.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrolyte Correction
Description: If the potassium level is greater than 6 mEq/L, do not administer potassium supplement. If the potassium level is 4.5-6 mEq/L, administer 10 mEq/h of potassium chloride. If the potassium level is 3-4.5 mEq/L, administer 20 mEq/h of potassium chloride.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Correction of Fluid Loss
Description: Initial correction of fluid loss is either by isotonic sodium chloride solution or by lactated Ringer solution. The recommended schedule for restoring fluids is as follows:~* Administer 1-3 L during the first hour.~* Administer 1 L during the second hour.~* Administer 1 L during the following 2 hours~* Administer 1 L every 4 hours, depending on the degree of dehydration and central venous pressure readings

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correction of Fluid Loss
Description: Initial correction of fluid loss is either by isotonic sodium chloride solution or by lactated Ringer solution. The recommended schedule for restoring fluids is as follows:~* Administer 1-3 L during the first hour.~* Administer 1 L during the second hour.~* Administer 1 L during the following 2 hours~* Administer 1 L every 4 hours, depending on the degree of dehydration and central venous pressure readings
Study: NCT04648345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinal plane block
Description: After induction of general anesthesia, pre-operative ultrasound-guided bilateral erector spinae plane block/ vertebral side block will be performed in the ESPB/VSB group. Local block will be performed at the surgical incisions after the surgery under general anesthesia. All the intervention will be performed without patients' awareness.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Erector spinal plane block
Description: After induction of general anesthesia, pre-operative ultrasound-guided bilateral erector spinae plane block/ vertebral side block will be performed in the ESPB/VSB group. Local block will be performed at the surgical incisions after the surgery under general anesthesia. All the intervention will be performed without patients' awareness.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinal plane block
Description: After induction of general anesthesia, pre-operative ultrasound-guided bilateral erector spinae plane block/ vertebral side block will be performed in the ESPB/VSB group. Local block will be performed at the surgical incisions after the surgery under general anesthesia. All the intervention will be performed without patients' awareness.
Study: NCT01168531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: pregabalin: 300 mg/day, po, from operative day until third postoperative day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone 16 mg, intravenous, before induction of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: vitamin B complex formula
Study: NCT01338493

Intervention type: PROCEDURE
Intervention: lumbar spinal arthroplasty + Maverick™
Description: All patients will be subjected to a lumbar spinal arthroplasty. The anterior lumbar spine is approached through either a transperitoneal or retroperitoneal exposure. A complete anterior discectomy is performed and the Maverick™ Artificial Disc System is inserted to replace the damaged lumbar intervertebral disc.
Study: NCT01472081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT00623662

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Preoperative normal saline infusion
Description: Normal saline infusion from 15:00 on the day before surgery until beginning of the operation.
Study: NCT02124512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin SSD
Description: Study Drug dosing will be 80 mg SSD once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 80 mg placebo once daily
Study: NCT01735669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide